Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies - PubMed (original) (raw)

. 2009 Apr;132(Pt 4):1093-101.

doi: 10.1093/brain/awn349. Epub 2009 Jan 20.

Affiliations

• PMID: 19155272
• DOI: 10.1093/brain/awn349

Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Katerina E Paleologou et al. Brain. 2009 Apr.

Abstract

A number of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy are characterized by the formation and intraneuronal accumulation of fibrillar aggregates of alpha-synuclein (alpha-syn) protein in affected brain regions. These and other findings suggest that the accumulation of alpha-syn in the brain plays an important role in the pathogenesis of these diseases. However, more recently it has been reported that early amyloid aggregates or 'soluble oligomers' are the pathogenic species that lead to neurodegeneration and neuronal cell death rather than the later 'mature fibrils'. In this study, we investigated the presence of alpha-syn oligomers in brain lysates prepared from frozen post-mortem brains of normal, Alzheimer's disease and DLB patients. The brain extracts were subjected to high speed centrifugation, to remove insoluble alpha-syn aggregates, followed by specific detection of soluble oligomers in the supernatants by employing FILA-1, an antibody that specifically binds to alpha-syn aggregates, but not to alpha-syn monomers, or to tau or beta-amyloid aggregates. Using this novel enzyme-linked immunosorbent assay (ELISA) method to quantify the amounts of alpha-syn oligomers in the brain extracts, our data clearly show an increase in the levels of soluble oligomers of alpha-syn in the DLB brains compared to those with Alzheimer's disease and the controls (P < 0.0001). Our findings provide strong evidence to support the contention that elevated soluble oligomers of alpha-syn are involved in the pathogenesis of DLB. Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of alpha-syn in human brain lysates.

PubMed Disclaimer

Similar articles

• Stabilization of α-synuclein oligomers using formaldehyde.
  Ruesink H, Reimer L, Gregersen E, Moeller A, Betzer C, Jensen PH. Ruesink H, et al. PLoS One. 2019 Oct 11;14(10):e0216764. doi: 10.1371/journal.pone.0216764. eCollection 2019. PLoS One. 2019. PMID: 31603909 Free PMC article.
• Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
  Vaikath NN, Erskine D, Morris CM, Majbour NK, Vekrellis K, Li JY, El-Agnaf OMA. Vaikath NN, et al. Neuropathol Appl Neurobiol. 2019 Oct;45(6):597-608. doi: 10.1111/nan.12531. Epub 2018 Dec 3. Neuropathol Appl Neurobiol. 2019. PMID: 30422353
• Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
  Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM. Vaikath NN, et al. Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30. Neurobiol Dis. 2015. PMID: 25937088
• Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
  Sengupta U, Kayed R. Sengupta U, et al. Prog Neurobiol. 2022 Jul;214:102270. doi: 10.1016/j.pneurobio.2022.102270. Epub 2022 Apr 18. Prog Neurobiol. 2022. PMID: 35447272 Review.
• Small molecule-based fluorescent probes for the detection of α-Synuclein aggregation states.
  Haque R, Maity D. Haque R, et al. Bioorg Med Chem Lett. 2023 Apr 15;86:129257. doi: 10.1016/j.bmcl.2023.129257. Epub 2023 Mar 24. Bioorg Med Chem Lett. 2023. PMID: 36966976 Review.

Cited by

• Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders.
  Ingelsson M. Ingelsson M. Front Neurosci. 2016 Sep 5;10:408. doi: 10.3389/fnins.2016.00408. eCollection 2016. Front Neurosci. 2016. PMID: 27656123 Free PMC article. Review.
• Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
  Ebrahimi-Fakhari D, Saidi LJ, Wahlster L. Ebrahimi-Fakhari D, et al. Acta Neuropathol Commun. 2013 Dec 5;1(1):79. doi: 10.1186/2051-5960-1-79. Acta Neuropathol Commun. 2013. PMID: 24314025 Free PMC article. Review.
• The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses.
  Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N. Jan A, et al. Int J Mol Sci. 2021 Aug 3;22(15):8338. doi: 10.3390/ijms22158338. Int J Mol Sci. 2021. PMID: 34361100 Free PMC article. Review.
• α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
  van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA. van Steenoven I, et al. Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15. Mov Disord. 2018. PMID: 30440090 Free PMC article.
• Stabilization of α-synuclein oligomers using formaldehyde.
  Ruesink H, Reimer L, Gregersen E, Moeller A, Betzer C, Jensen PH. Ruesink H, et al. PLoS One. 2019 Oct 11;14(10):e0216764. doi: 10.1371/journal.pone.0216764. eCollection 2019. PLoS One. 2019. PMID: 31603909 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal